MiR-142 is found to be hypermethylated in HCC, and the methylation inhibitor 5-azacytidine (5-Aza) can restore miR-142 expression to inhibit proliferation, epithelial-mesenchymal transition, and pro-angiogenesis in a TGF-β-dependent manner in HCC, which also partially explains why reduced expression of miR-142 is linked to poor clinical outcomes in HCC [41]. The gene discussed is TGFB1; the disease is hepatocellular carcinoma.